NephroGuard has been selected as one of the Unirein Third-Party experimentation projects.
Bio Logbook's NephroGuard project joins forces with Unirein to optimize the management of chronic kidney disease (CKD). A magnificent consortium bringing together the best expertise in the field of kidney disease.
Promising collaboration to revolutionize CKD treatment
We are delighted to announce that our NephroGuard project has been selected as one of the experimental projects of Tiers-lieu Unirein, a consortium of excellence bringing together the best experts in the field of kidney disease. This collaboration marks an important step forward in our mission to optimize the management of CKD thanks to the innovative digital solutions developed by Bio Logbook.
Unirein: A catalyst for innovation in kidney disease
The Tiers-lieu Unirein is an ambitious initiative aimed at transforming the management of renal and metabolic diseases in France. This unique hub brings together key players in the sector, such as researchers, clinicians, manufacturers and patients, around a common goal: to accelerate the development and adoption of innovative solutions to improve the quality of life of CKD patients.
NephroGuard: A digital solution for patients
NephroGuard is a digital solution designed to support CKD patients in their care. This intuitive platform enables patients to track their health status in real time, receive personalized advice and connect with their medical team. NephroGuard has already demonstrated its effectiveness in improving patient health outcomes and reducing healthcare costs.
A promising collaboration for the future
Our participation in the Tiers-lieu Unirein will enable us to benefit from an environment conducive to innovation, and to collaborate closely with world-renowned experts. We are convinced that this collaboration will accelerate the development of NephroGuard and make it a key solution for the management of CKD in France.
Live from Bio Logbook.
Find out about our latest news, collaborations and study projects.